On August 14, Boston Scientific rose 3.85% in pre-market trading, trading at $53.68/share, with turnover of $158,000, extending its post-earnings recovery trajectory.

The move continues to be driven by the company's Q2 earnings beat and global restructuring plan disclosed in late July. Boston Scientific reported Q2 adjusted EPS of $0.86, exceeding the consensus estimate of $0.83 by 3.6%, while net sales of $5.44 billion topped the $5.36 billion expectation. The company simultaneously announced a global restructuring program with estimated pre-tax charges of $700 million to $800 million, targeting annualized pre-tax cost savings of $500 million through supply chain optimization and headcount reduction, expected to be substantially complete by end of 2029.

Despite the company lowering full-year adjusted EPS guidance to $3.28-$3.32 versus the $3.36 Street estimate due to Watchman device slowdown and electrophysiology competitive pressures, multiple institutions including UBS and Deutsche Bank maintained Buy ratings with adjusted price targets, supporting the ongoing recovery from post-guidance-cut lows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)